IUIIIC Z I I I~ ( Z~I J
h:lr I,UCII rcp.~rtcJ to ~~I I : I I I . C b~l~d~r~g of h u n~a r~ growth h$,rmonc (hG1 I). ~I I I I rl.)t rol.1~1111 (PRL), IL) tllc humdn PRL receptor at a col!ccnlr.ttl.)n of -5tluAl A\. We h;&c ~n\,t.su,'.ttcJ ~h c cficct of zinc on hGH bioactivi , using a lactoge~i;bioassay.~he pot;ncies of selected doses of both h G H a n 2 P R L in the rrsence of increasing concentrations of ZnCl were investigated with an ~f u t e d Stain Assay (ESTA) which used Nb2 celz. This colorimrtric bioassa is based upon the reduction of a yellow tetrazolium salt, M T , t o its purple formazan by 1:tctogen-activated Nb2 cells. Zinc enhanced the bioactivlt of h G H but not PRL. Pro ressive enhancement of a low dose (O.SmU/L; &M) of h G H I R P 80/!05; was observed over t h e Z n concentration range af 6-100uL; higher Zn concentrations were inhibitory.
Potentiation of bioaciivity was observed only with low doses of hGH; with >2.5mU hGIJIL, 50uM Zn inhibited the response. The bioactivity of PRL was conststently inhibited by 50uM Zn (PRL range 0.2-50mUL; 0.4-105pM), inhibttion being greater with higher P R L doses. We conclude that in this precise and sensitive bioassay, zinc has a differential effect on hGH and PRL bioactivities which concords with the radioligand studies but potentiation of bioactivity was only observed with low h G H doses. It was optimal at -50uM Z n but was far lers than might have been anticipated from the binding studies, when the affinity increased by 8000-fold. This discrepan was not explained by significant endogenous Z n in the bioassay m e d t u m z n l y 2uM by Atomic Absorption Spectroscopy). Our findings therefore do not su port the earlier suggestion (1) that Zn is crucial for the lactogenic bioactivity o f h~~. Physiological growth hormone (GH) secretion incre:~ses during puberty and it has been su 7 rected that similar changcs should be made to the therapeutic schedules of k1l:insufficient children receiving G H therapy. We have tested this hypothesis in 50 GH-insufficient children aged between 9.7 and 14.5 years who ere randomised to continue with biosynthrtic hum G H at a dose of 15 ~lm~heeueek (Group A) or to an increased dose of 30 ~lm'heek Group B), at breast stage 2 development in girls and at a testicular volume of mls in boys. All children had received G H treatment prior to randomisation for at least 1 year. There was n o difference between the groups prior t o randomisation in terms of age, height and height velocity. Pubert was entered at a similar mean age: 11.8 years (SEM 0. The dual energy x-ray absorptiometry (DEXA) technique t o measure bone density may also provide estimates of body composition, abnormalities of which a r e a well recognized consequence of growth hormone deficiency. To assess the precision of the method in c l~n i c a l practice, we have compared estimates of t o t a l body water by DEXA (Hologic QDR 1000/W) with those obtained from skinfold thickness and bioelectrical impedance measurements in 10 patients aged (range) 14.0 t o 17.9yrs. receiving growth hormone therapy. Unilateral asphyxia1 neuronal injury was induced in rats by carotid ligation followed by mhnlational asphyxia. Infarction and neuronal loss occurs in the ligated hemisphere. In situ hybridisation showed enhanced expression of IGF-1 by glia and of its binding proteins BP-2 and BP-3 withln 24-72 hours of injury although the d~stribution of expression showed differences. In contrast IGF-2 and BP-5 were induced much later not appearing for 7-10 days post injury. BP-4 was suppressed on the side of injury. IGF-I was administered to adult rats via the lateral ventricle.
Treatment 2 hours after injury led to a dose dependent reduction in infarction from 87% to 26% @<0.05) over the dose range 5 to 50pgIrat. Funct~onal testing showed protected somatosensory function in the treated rats compared to sham controls. The effect of IGF-1 was not mimicked by des 1-3 IGF-1 suggesting an Important role for the induced BP-2 or BP-3. Insulin had a weaker effect than IGF-1 and no protective effect of IGF-2 was observed: compatible with an action at the type 1 IGF receptor. Treatment prior to injury had no effect suggesting that IGF-1 acts via interfering with apoptosis. Thcsc observations suggest endogenous IGF-1 production is enhanced following neuronal injury as a protective response and suggests that exogenous IGF-I might be a potential neuronal rescue therapy. RNA wis denatured i n $ y i x~~~~~ ark-electropnotesed on 0 8 % agarose RNA was fansterred to a nylor mmaane by capllan, nanslm flxed and tne Mocs hya&cxl wan cDhA p o x s A 614 @ PSI I haQneR of me IGF-I r m a cDM an3 a 663 tp h a q n m ol the IGF-IIIMGP r m a cDNA were labeleo wan 3 2~d~~~ usrg randm prune labllng Autaadrographs 01 hlmnern blas shorrea a 11 k b ban3 wnh tne IGF-I recepta pobe Hybrdlzalm wllh UX iGF-IIIMGP recepa pobe yielded a 9 kb RNA spec%. In a stlbser of experiments a Pst I 700 bD fraunenl of me IGF-l cDNA an3 a 833 t~ PSI I ha~nent of the IGF-II cDNA, were used i a hybriizalm: no hybridization was detected w~h ihe IGF-I p&. Howevw, us@ me 32~-IGF-II probe bands a 8.4. 5.3 and 5.0 kb were *led. In adlm. C~COZ d s were cullwed mil confluency, darged serun-he9 an3 celicondiiooed medium was harvesied . IGF-ll hmumeac(ivity was measued using an IGF-binding praein block& radioimmunoassay. CaCo2 cell-condilioned medium contained 1-2 nglml IGF-iI immumeadivity. In cmlusion. (1 Our data indicate that i n splte of the fact that before any treataent, the studled groups d~d not dlffer in term of BA and GY, before lnstttutlon of GH therapy, a stal~rt~cally s!gnlf!cant d~fference was found between BA and GY in both groups It 18 diff>cult to conclude on the basis of our saterlal l f the GV in group I during GH treatlent was dependent mainly on pietreatnent vtth GHRH or rere more advanced 81 andlor htgher GY before initiation of GH therapt also decislve factors In the group treated k i t h GHRH, no correlation has round between the GV in rrsponse to 6H and the GV observed d u r j n p GHRH treatment ir : -0.11, p -nsi The prouth response to GHRH does not seem to be a prognostx of response to GH therap).
